Introduction
Alzheimer's (AD), Parkinson's (PD), and Huntington's disease (HD) share the property that mitochondria (MT) do not keep up with the energy demands of the cell (Arun et al., 2016; Carvalho et al., 2015; Chaturvedi and Flint Beal, 2013; Lane et al., 2015) . However, AD, PD, and HD display region-specific cell death (Chaturvedi 2003; Quintanilla et al., 2013) , abnormalities in calcium dynamics (Duchen, 2012; Lim et al., 2008; Panov et al., 2002) , and low ATP production (Gines et al., 2003; Seong et al., 2005 ), yet these well-established properties have not directly led to an obvious understanding of the age-and region-specific nature of the disease.
The early disturbances in the HD brain are likely to be the source of toxicity and the most effective point of therapeutic intervention. However, the basis for early toxicity and region-specific sensitivity is unknown, and is one of the most puzzling aspects of this disease. Impaired ATP production and bioenergetics are widely reported, but the results are often inconsistent, and vary depending on sample. e.g., the particular HD model mouse strain used, the age at the time of the measurements, and whether the system was a tissue, cell, or purified MT, and the buffer conditions under which they were measured. The effect of some of these factors on measurements has been noted previously (Brustovetsky, 2015) . It remains enigmatic whether MT effects are a primary cause or a late-stage consequence of toxicity. The role of MT, therefore, needs to be clarified. In this review, we will focus on the bioenergetics in models of Huntington disease, taking note of the sample source, strain, age, and buffer conditions to address whether mitochondrial dysfunction occurs, and how much it contributes to disease progression. The major results are compiled in a Table summary (Table 1) .
Due to the sheer volume of information, (1) we restrict the review to only HD, the caveat being that there may be key metabolic differences among neurodegenerative disorders, and that the discussion would not be able to include all the published work. (2) We will divide as best we can the observations in the literature into two groups; those that are directly related to metabolic dysfunction and those whose association is circumstantial, i.e. not accompanied by direct measures of mitochondrial respiration. The latter are considered to be important, but cannot be distinguished from the effects due to concomitant processes such as inflammation and/or aging. (3) Distinctions in rodent models are made between the transgenic animals with the N-terminal truncated forms of the mutant Huntington gene (mHtt) and the full-length (FL) endogenous forms, which would help highlight any distinction between these model systems.
Evidence for mitochondrial dysfunction in human tissue
Early work in postmortem human brain provided the first evidence that alterations or reduction in mitochondrial electron transport chain (ETC) components or their activity were abnormal (overview of ETC and Glycolysis: Fig. 1 ). The most notable changes are loss of complexes II and III (Browne et al., 1997; Fukui and Moraes, 2007; Vonsattel and DiFiglia, 1998; Vonsattel et al., 1985) , and to a lesser extent deficiency of complex IV in the caudate or putamen (Vonsattel and DiFiglia, 1998; Vonsattel et al., 1985) . In postmortem brain specimens from 163 clinically diagnosed cases of Huntington's disease (HD), Vonsattel developed a categorization system, which ordered the macroscopic and microscopic criteria into five grades (0-4) in ascending order of severity (Vonsattel and DiFiglia, 1998; Vonsattel et al., 1985) . In grade 1 disease, neuropathological changes are recognized microscopically in the medial paraventricular portions of the caudate nucleus (CN), an observation that has driven research. However, in grade 0 brains, clinically diagnosed, but pre-symptomatic HD patients display no loss of mitochondrial ETC activity, suggesting that their alterations do not precede the onset of symptoms in an obvious manner. At what stage MT "go bad" is unknown, and whether this transition is a primary cause of the pathophysiology remains enigmatic. Based on the classification work of Vonsattel et al. (1985) , the general suppression of mitochondrial activity seems to occur at later stages of disease progression, but not early on.
Defects in oxygen consumption in human postmortemj brain
So, is there general agreement as to mitochondrial dysfunction at later stages in postmortem human brain? The bulk of the existing data for human brain would support the notion (Table 1) . Early ultrastructural studies obtained from the cerebral cortical tissue of HD patients reveal abnormal mitochondrial morphology (Goebel et al., 1978; Tellez-Nagel et al., 1974) suggesting that they are affected in the disease state. However, as reported by others, the specific abnormalities in mitochondrial respiration of postmortem symptomatic patients do not necessarily accompany these changes, or, minimally, the relationships are inconsistent among brain samples. As judged by spectrophotometric (SPECTR) assays, the activity of the ETC enzymes are impaired in the basal ganglia of HD brains, while enzyme activities were unaltered in three regions relatively spared by HD pathology (frontal cortex, parietal cortex, and cerebellum) (Browne et al., 1997) . In the most affected region of the HD brain, the striatum, complex II-III activity are markedly reduced in both caudate (−29%), while Complex II-III (−67%), and IV (−62%) are altered in the putamen (Browne et al., 1997) . Another study concurred that complex III and IV are altered in human HD brains, although the regional patterns are slightly different; a decrease in activities of complex II-III occurs in the caudate and putamen, while complex IV is reduced in the putamen. Thus, it appears that mitochondrial dysfunction as indicated by loss of ETC activity, aligns with the region-specificity of degeneration, although the exact complexes that are affected are variable. Surprisingly, there is, for the most part, a failure to identify defects in ETC complex I in the HD brain. Complex I is the gateway for electron flow in the ETC, and blocking it is expected to have detrimental consequences for energy production. Thus, it is notable that complexes II-IV but not complex I are associated with human disease. It is possible that complex I defects are toxic enough to lead directly to cell death (and therefore cannot be observed). Arguing against this idea, however, are observations that rotenone inhibition of Complex I in mice is not lethal. Indeed, inhibiting it results in symptoms reminiscent of Parkinson's disease (Schapira and Gegg, 2011) .
More important in HD brain seems to be the function of ETC Complex II (Benchoua et al., 2006; Gu et al., 1996; Tabrizi et al., 1999) . Deficiency of respiratory chain complex II, i.e., succinate dehydrogenase (SDH), has been a focus of attention in HD due to the fact that the inhibition of succinate dehydrogenase (SDH) by or malonate closely mimics the neuropathology and clinical features of HD in humans (Myers et al., 1991) , in non-human primates (Palfi et al., 1996) , and in rodents (Brouillet et al., 1998) . Similar to humans, administration of 3-NP in rats not only inhibits complex II, but it also inactivates mitochondrial complexes III, IV and V in the striatum, without significant effect on complex I (Pandey et al., 2008) . Whether impairment of complex II always inhibits the downstream complexes of the ETC chain, or always impairs electron flow through complex I is not yet clear. At least in vitro, classic ETC inhibitor analysis indicates that succinate stimulation of complex II is unaffected under conditions of rotenone inhibition of complex I (Oliveira et al., 2007) . Complex II oxidizes succinate, which, in TCA cycle, leads to accumulation of oxaloacetate, an inhibitor of Complex II. Rotenone inhibits Complex I and maintains a high level of NADH, which prevents oxaloacetate accumulation and Complex II inhibition, suggesting that inhibition of complex I would increase the demand on complex II, but not eliminate energy production. Consistent with a critical role for complex II in HD, there is loss of its components, the 30-kDa iron-sulfur (Ip) subunit and the 70-kDa FAD (Fp), in primary striatal neurons when infected with lentiviral vectors encoding mHtt. Similarly, overexpression of Complex II components leads to significant neuroprotection (Damiano et al., 2013) . Deficits in SDH have significant consequences, since it is a component of both the ETC as well The ETC uses NADH and FADH2 to make ATP. These reducing equivalents for ETC are generated during glycolysis, fatty acid breakdown, and in the Tricarboxylic Acid pathways (TCA), also known as the Krebs cycle. The electron flow starting from NADH binding to complex I or from succinate/FADH2 binding to complex II initiate electron flow that ultimately results in ATP production in Complex V, the ATPase. If these pathways malfunction, ATP production is reduced, placing stress on the cell.
as the tricarboxylic acid (TCA) cycle (Stahl and Swanson, 1974) , and will presumably have effects on both energy-producing pathways.
As judged by SPECTR measures, a reduction of complex II subunit expression in some HD patients occurs in the striatum, consistent with the region-specific deterioration of the disease (Benchoua et al., 2006) . In sum, most of the ETC complexes have been identified as defective in at least one region of the HD brain in postmortem HD brain, clearly indicating that there is very likely to be a bioenergetic defect especially late in disease progression. These human studies have the obvious and unavoidable problem that human postmortem brain is assessed after some postmortem delay, which has consequences that are not fully understood. The integrity of some cells will be compromised and perhaps identifying consistent quantitative differences in ETC content among regions is beyond the sensitivity of postmortem studies. The results also raise several puzzling questions. The basis for the relative importance of complex II and the relative lack of defects in complex I in HD postmortem tissue are unclear. If they represent independent electron entry points, why should complex II be critical to HD striatum if complex I is still functional? If inactivity of the ETC enzymes is a cause of toxicity, why is it limited to particular regions? Regional toxicity could be explained by cellular metabolism that fails to optimally fuel MT in particular regions. Indeed, metabolic abnormalities have been reported, particularly in glucose production or uptake (Kuhl et al., 1985; Kuwert et al., 1990; Mazziotta et al., 1987; Pagano et al., 2016) and in fatty acid metabolism (Carroll et al., 2015; Mochel and Haller, 2011) , although the mechanism for either of these alterations is unknown. If mitochondria are defective, the expectation is that they are non-functional. However, there is considerable debate as to whether MT are metabolically hypoactive or hyperactive in the disease state (Mochel and Haller, 2011; Weydt et al., 2006) . This paradox is also as yet unexplained.
In the presence of a fully functional complex I, the expectation is that a complex II defect would appear, on the surface, to be metabolically tolerable, and loss of complex I would not preclude energy production through complex II, although inhibition of either complex I or II is not expected to be beneficial. Thus, an important unresolved question is how much ETC activity is required to maintain energy output before deficits approach a critical level. Indeed, the threshold for inhibition of individual ETC complexes varies considerably. In normal rat tissues, there is variability in the degree to which inhibition of distinct ETC complexes influences mitochondrial function (Rossignol et al., 1999) . Titration of complex I, III, and IV with specific inhibitors generates threshold curves that indicate the extent to which a complex activity can be inhibited before causing impairment of mitochondrial energy metabolism. For complex I, complex II/III, complex III, and complex IV, the inhibition thresholds are 10-25, 30, 35, and 50-65%, respectively, before major changes in OCR are observed (Davey et al., 1998; Mazat et al., 1997; Rossignol et al., 1999; Telford et al., 2009) . Since complex I and II are the major entry point for electrons, it makes sense that their inhibition would have the most dramatic effects on OCR, yet the impact of complex inhibition, particularly IV, is surprisingly small; nearly 70% of the enzyme is dispensable to maintain energy output. The activity of complex III or IV is most commonly lost or dysfunctional in HD human brain from postmortem analysis. If the results in rats apply to humans, these deficiencies are predicted to have only modest effects in the HD brain.
Mutations in the electron transport chain do not characterize HD, AD, or PD. However, it is of interest to note that point mutations in mitochondrial genes coding for several subunits of complex I (NADH:ubiquinone oxidoreductases) can lead to putaminal degeneration and dystonia, reminiscent of the striatal vulnerability to impairment of oxidative phosphorylation at the genetic level (reviewed in Damiano et al., 2010) . For example, striatal atrophy results from homozygous point mutation in subunits of complex III, ubiquinol-cytochrome c reductase (Estrada-Sanchez and Rebec, 2012). Impairment of ETC enzymes, on their own, results in tissuespecific death similar to that observed in HD. This bolsters the idea that tissue-specific toxicity in regions affected by HD can arise from defective oxidative phosphorylation.
So, is mitochondrial dysfunction a cause or a consequence of HD toxicity? As judged by data from human HD brain, it seems clear that mitochondrial dysfunction is generally present in late stages of disease progression, which would be more consistent with dysfunction being a consequence of toxicity. However, there are key pieces of missing data to consider in answering the question. Neurons die in particular regions of the brain, yet in postmortem tissue, there has not been consistent normalization of OCR for neuronal number or citrate-dependent activity, or mitochondrial copy number, which would account for the changes in number of neurons and MT in the sample. This could make a significant difference in the interpretation. Indeed, in living patients, normalizations for cell number changed the interpretation of the raw data as to the significance of the complex I and II defects in blood cells of HD patients (Ehinger et al., 2016) . These authors concluded that blood was not a reliable source to discern bioenergetic differences in patients. In the brain, a regional reduction in bioenergetics and ETC complex expression will occur if neurons have died. Thus, at least some of the bioenergetic reductions reported in the literature for human brain may reflect cell death rather than relative mitochondrial dysfunction, and without normalization, it is not possible to distinguish between them. Consistent normalization should be a goal in future studies.
A second issue is the role of astroglia, whose effects are largely unresolved from those of neurons in postmortem brain. While neuronal death is a major phenotype, most regions of the brain comprise primarily non-neuronal cells such as astrocytes (Gu et al., 2007; Gu et al., 2005; Pekny et al., 2016) . In tissue of HD patients, astrogliosis also accompanies neuronal death (Faideau et al., 2010; Vonsattel et al., 1985) . Counts of neurons in the caudate however reveal that 50% of the neuronal cell population are lost in grade 1 and that 95% are lost in grade 4 HD, suggesting that changes measured in the commonly available grade 3 and 4 tissue would mainly reflect the function of the surviving astrocytes (Vonsattel et al., 1985) .
The communication between neurons and astrocytes is a critical feature of brain physiology (Allen, 2014; Osborn et al., 2016 ), yet respiration in these support cells and their impact on the HD disturbances are largely unknown. One recent report suggests that neuron-glial signaling has a key role in HD, at least in a mouse model expressing a truncated fragment of mHtt (Boussicault et al., 2014 ), but have not been followed up in other analyses. Whether defects in astrocyte bioenergetics are significant in HD tissues, other mouse models for HD, and cells will be important to determine. Finally, the CAG repeat tract size among somatic cells contributes to toxicity. The longer the tract length of the expressed gene, the more defective is the expressed protein, which is predicted to have a larger impact in humans on cellular respiration and pathophysiology if mHtt causes the defects (Swami et al., 2009) . Recent analysis of somatic expansion verifies that this is the case. Blocking somatic expansion in mice suppresses pathophysiology (Budworth et al., 2015; Budworth and McMurray, 2016) , indicating that somatic changes in repeat tract number during life contribute to toxicity in addition to the inherited expanded allele. The regional variability in energy deficits may reflect, at least in part, the individual cell variations in the CAG tract length among brain regions (Budworth et al., 2015; Budworth and McMurray, 2016; Swami et al., 2009; Kennedy et al., 2003; Kennedy and Shelbourne, 2000) . Thus, multiple contributions have an influence on neuronal survival, which affects the heterogeneous composition of cell types and complicates an already complicated bioenergetic explanation of toxicity at late stages of the disease. A full analysis including repeat length, normalization for mitochondrial number, and cell number should be applied to raw data and considered before the results among studies can be compared, and before determining the significance of a bioenergetic defect.
Whatever the quantitative impact on the ETC, glycolysis is unlikely to compensate for the OCR deficits from a complex I or II defect. In fact, most of the indications are that parallel metabolic processes also are not optimal. The activity of aconitase, an essential enzyme in the TCA cycle, is significantly decreased in the striatum and cerebral cortex (Tabrizi et al., 1999) , GADPH is impaired by faulty autophagy (Hwang et al., 2015) , loss of the pyruvate dehydrogenase complex is detected even in asymptomatic patients with caudate/putamen atrophy (Butterworth et al., 1985; Sorbi et al., 1983) , glucose uptake is low in HD patients (Pagano et al., 2016) , and it is also widely reported that glycolytic rate is reduced in some rodent models of HD (Gouarne et al., 2013) .
Defects in oxygen consumption rate in peripheral human tissues
While postmortem HD brain is arguably the most relevant tissue, it is also the most problematic. There is no good way to normalize for the effects of oxidative damage and postmortem delay on the function of MT. Human peripheral tissues from living patients may be better predictors of mitochondrial contributions to toxicity (van der Burg et al., 2009 ). Muscle and lymphocytes have received the most attention in this regard, although the bioenergetic profiles are inconsistent among patient populations. Similar to neurons, changes in mitochondrial morphology, as measured by electron microscopy, are obvious in lymphoblasts (Squitieri et al., 2006 (Squitieri et al., , 2010 , suggesting that, at least structurally, there are abnormalities. However, in contrast to the brain, complex I, and not complex II, emerge as common impairments in peripheral tissues.
For example, in peripheral blood cells from 14 HD patients and 21 control subjects, direct measurements with a respirometer resulted in detection of statistically robust deficiencies only in mitochondrial complex I (Ehinger et al., 2016) . Mitochondrial spare respiratory capacity is a measure of the ability of mitochondria to generate energy beyond that required for sustaining the basic metabolic needs. Epstein-Barr virus immortalized HD lymphoblasts (of 70-120 CAG repeats and from unspecified patient age/sex) display a decrease in mitochondrial basal respiration, spare respiratory capacity, ATP coupling efficiency and rate of glycolysis compared to controls (Mejia et al., 2016) . Moreover, the complex I enzymatic activity was reduced in preparations of mitochondrial enriched samples in HD lymphoblasts compared to control cells (Mejia et al., 2016) , and the physical complex I supercomplexes activity was reduced. These changes did not vary among HD patients with different length of CAG repeats relative to controls. In contrast, loss in complex I function in lymphoblastic cells in another HD patient population biopsied between 15 and 60 years (Arenas et al., 1998) correlate with the patients of longest CAG expansion sizes, supporting the notion that the relationship with expansion is related to disease severity (Arenas et al., 1998) . Collectively, in peripheral cells, there is remarkable agreement on the involvement of complex I, but the relationship to CAG tract length is in question.
The implication of complex I deficiencies in other peripheral cells is notable. Indeed, Complex I was reduced in platelets (Parker et al., 1990 ), but not affected in another study (Powers et al., 2011) . There are no defects in the activities of complex II and IV in a study of HD patient muscle (Turner et al., 2007) , although complex I was not measured. ATP production, as measured by MRI or oxygen uptake, is significantly reduced in muscle of both presymptomatic and symptomatic HD patients (Lodi et al., 2000) . Specifically, mitochondrial deficiencies are evident by an increase in lactate production, ATP depletion, and reduced ability to generate phosphocreatinine (a high-energy phosphate metabolite and energy reservoir used for the rapid generation of ATP) (Lodi et al., 2000) . The results suggest that in mitochondrial dysfunction occurs before the onset of symptoms in peripheral tissue.
An integrated conclusion is difficult to draw. Peripheral tissues of HD patients often (but not always) appear to have defects in complex I. This is in contrast to complex II, III, and IV loss, which is typically observed in postmortem brain. However, low ATP in muscle of pre-symptomatic patients is not consistent with the lack of ETC defects observed in pre-symptomatic postmortem HD brains by Vonsattel et al. (1985) . Living tissue either provides a more stable and reliable source for mitochondrial analysis and a postmortem state is too late to observe energy defects, or there are distinctions among tissues, i.e., defects in complex II and I align with distinct tissue types. If significant, there may be a poorly described but potentially important organ-specificity to energy metabolism or MT characteristics in HD patients. More work will be needed to sort whether there are robust differences.
Rodent models and cell lines
The obvious difficulty in delineating cause and effects of mitochondrial dysfunction and toxicity in postmortem HD brain and peripheral tissues underscores the importance of mouse models from which evaluation of brain and peripheral tissues can be performed during disease progression. However, results from mouse models have not clarified issues. While useful in delineating mechanisms of toxicity, data from mouse models have arguably raised more bioenergetics questions than they have answered. Extensive bioenergetics data are available for mouse models of HD expressing either a full-length endogenous gene or a truncated N-terminal fragment. There remains a substantial debate as to whether the two models are equivalent, and we will consider each of them (as well as rats) separately.
Mitochondrial binding of FL-mHtt and FL-Htt
Mitochondrial localization of truncated mHtt and FL-mHtt as detected by immunocytochemistry and electron microscopy raised the issue as to whether a direct interaction between mHtt and mitochondria might be detrimental (Brustovetsky, 2015) . Indeed, in the mitochondrial fraction purified from HdhQ(111/111) mice, mHtt is associated with the outer mitochondrial membrane (Choo et al., 2004; Panov et al., 2002) , and exogenous addition of purified GST-mHtt truncated fragments of 63Q but not 25Q to purified MT can induce a toxic transition pore (MPTP) opening and mitochondrial swelling (Choo et al., 2004) . The mitochondrial permeability transition pore (MPTP) is a large conductance channel in the inner mitochondrial membrane, and its opening can lead to cytochrome c release and cell death. It is unclear in the latter studies how mhtt fragments initiate cell death, since they are present externally. However, toxicity is clearly observed.
Based on these findings, it is reasonable to conclude that association of mHtt with MT is a phenotype of the disease state. However, there is no general consensus on this point. Both Htt and mHtt are large scaffold proteins involved in moving MT and other vesicles along microtubules tracts (Damiano et al., 2013; Harjes and Wanker, 2003; Trushina et al., 2004; Trushina et al., 2006; Trushina et al., 2013) , and both bind to trafficking adaptors, motor proteins, and to cytoskeleton components (Harjes and Wanker, 2003; Trushina et al., 2004 Trushina et al., , 2006 Trushina et al., , 2013 . Thus, their presence on and around MT is expected, and not necessarily part of disease etiology. For example, the FL protein harboring normal (htt) or mutant (mhtt) polyglutamine lengths bind to MT in YAC128 mice (YAC: yeast artificial chromosome) (Hamilton et al., 2015) and in immortalized striatal cells (STH) from HdhQ(111/111) mice (Choo et al., 2004) . In the YAC128 mouse, the amount of bound Htt is four-times higher than the amount of bound mHtt (Hamilton et al., 2015) . MT are difficult to work with and easily damaged during isolation. Thus, a causative relationship between direct mHtt mitochondrial binding, and the degree of mitochondrial dysfunction in HD brain is not clear based on mhtt association with MT alone. But, bioenergetics effects in mouse models for HD toxicity are highly variable (Table 1) .
Bioenergetics in rodent models of HD
The effects of mHtt on OCR in animals have been informative, but seem to differ depending on the length of CAG repeat tract in the strain. Nonetheless, there are trends. Animals with disease-length CAG repeats inserted into the endogenous mouse gene (a knock-in), or in a rat model (Gellerich et al., 2008) develop pathophysiology slowly, and are good models for late onset and pre-symptomatic stages of HD. These animals typically live as long as their wild-type counterparts but develop features of disease between 1 and 2 years. The bioenergetics properties of many FL-models have been characterized, but the most comprehensive analysis was reported in the YAC128 mice (Hamilton et al., 2015) . The basic features can be summarized: the mitochondria of YAC128 mice and age-matched WT littermates did not differ significantly. The two genotypes have similar respiratory and glycolytic rates (in glucose and pyruvate) (Hamilton et al., 2015) , and are similar in O 2 consumption, CO 2 release, physical activity, food consumption and fasted blood glucose. There are some normal region-specific differences in that striatal neurons had lower maximal respiration compared with cortical neurons, but no abnormalities in mitochondrial membrane potential or ADP and ATP levels in either region relative as to controls. The detailed results argue against OCR deficiency in YAC128 mice, and suggest that mitochondrial respiratory dysfunction is not essential for HD pathogenesis.
Indeed, the results from YAC128 animals seem to reflect the activity of many animals expressing the full length endogenous (FL-Htt) gene, the most common being YAC72 (Reddy et al., 1998), YAC128 (Hodgson et al., 1999) , HdhQ(150/150) (Lin et al., 2001) , HdhQ(111/111) (Wheeler et al., 1999) , mouse BAC-HD (BAC: bacterial artificial chromosome) (Gray et al., 2008) , a rat-HD (expressing cDNA of the human gene with 51 CGG repeats) (von Horsten et al., 2003) , and a rat BAC-HD (von Horsten et al., 2003; Yu-Taeger et al., 2012) , which express polyglutamine tracts of 72, 128, 150, 111, 96, 51 , and 97 residues, respectively. For example, no differences in OCR or ETC enzyme activity are obvious in striatal neurons from BAC-HD mice (Boussicault et al., 2014) , in striatal MT from BAC-mice respiring on rich media (containing both glucose complemented with pyruvate) (Gouarne et al., 2013) , in HdhQ150/150 (Oliveira et al., 2007) or in YAC128 (Oliveira et al., 2007) , and in cortical or striatal MT from HdhQ(111/111) (Brustovetsky et al., 2005 ) when compared with wild-type controls.
However, the answer may not be so clear-cut. It would be expected that MT from tissue of HdhQ(111/111) animals would be similar to that of a cell line derived from the striatum of these animals (STHdh Q 111 ) (Trettel et al., 2000) (Table 1) . However, experimental results indicate notable differences. STHdh Q 111 cells expressing mutant huntingtin or MT from these cells show higher basal levels of mitochondrial-generated ROS and mtDNA lesions (Siddiqui et al., 2012) , lower spare respiratory capacity (Siddiqui et al., 2012; Milakovic and Johnson, 2005) , reduced oxygen consumption, and decreased Complex I, IV and V activities (Napoli et al., 2013) . In purified MT, the presence of mutant huntingtin impairs mitochondrial ATP production (Gines et al., 2003; Seong et al., 2005) and mitochondrial respiration. In STHdh Q 111 cells, there is substantial decrease in ATP/ADP levels that increases with tract length (Seong et al., 2005) , which is highly suggestive of a respiratory chain defect (Gines et al., 2003; Seong et al., 2005) . Moreover, survival after 3-NP treatment, an irreversible complex II inhibitor, is 2.5-fold lower in mutant lines relative to wild-type counterparts (Gines et al., 2003) , as judged by a metabolic activity assay of mitochondria (MTT assay). This method is based on the reduction of the soluble yellow MTT tetrazolium salt to blue insoluble MTT formazan product by mitochondrial succinic dehydrogenase, whose absence indicates non-viable MT (Gines et al., 2003) .
All of these parameters in STHdh Q 111 cells, in contrast to the mouse MT, paint a consistent picture of mitochondria dysfunction, except for the fact that the bioenergetics defects were not accompanied by deficiencies in ETC enzymes, as judged by inhibitors (Milakovic and Johnson, 2005; Milakovic et al., 2006) . The basis for the paradox is unknown, but may suggest that metabolic dysfunction rather than a mitochondrial dysfunction is operational. Specifically, a metabolic defect in the cells may not sufficiently fuel MT to generate ATP, although the enzymes could make ATP if provided with sufficient substrates. If correct, resolution of the issue may provide clearer evidence for metabolic dysfunction as a consequence and not a cause of impairment. Since both the HdhQ(111/111) mouse and the STHdh Q 111 cell lines are popular models for HD, it will be critical to establish whether or not the mouse and STHdh Q 111 cell lines are bioenergetically equivalent inside-by-side experiments using identical conditions. In vivo, aging in animals could provide opportunities to effectively remove damaged MT, restore OCR, or to enhance mitochondrial biogenesis, and may not be possible in cell lines. More in depth analysis is needed to resolve these issues.
In contrast to full-length mouse models, many fragment model mice display mitochondrial dysfunction even as presymptomatic animals. Well studied models include R6/1, R6/2 (Mangiarini et al., 1997) , and the D9-N171-98Q (Brown et al., 2008) , which express around 100 amino acids in the N-terminus of mHtt and have polyglutamine regions of roughly 117, 130, and 98 repeats, respectively (at the time of their construction). The R6/2 animals exhibit rapid death around 12 weeks, while the R6/1 animals live longer, but begin to have seizures around 1 year and decline from there. These mice best model severe, early onset HD. It is not clear whether the fragment models simply exacerbate energetic defects relative to full-length models, or produce different effects due to the rapid onset of death. In general, however, the evidence for mitochondrial dysfunction in the fragment models is inconsistent. For example, there is a reduction in succinate and OCR in the striatum of pre-symptomatic D9-N171-98Q mice compared with their wild-type littermates (Kim et al., 2011) , suggesting early complex II impairment. Similar results were observed in the forebrain of the same animals (Damiano et al., 2013) . In agreement with the D9-N171-98Q mice results, expression of the 30 kDa Iron-Sulfur (Ip) subunit of complex II is significantly reduced in the striatum of R6/1 animals, although the levels of the FAD containing catalytic 70 kDa subunit (Fp) are not significantly affected (Tabrizi et al., 2000) . The impairment of complex II is reminiscent of human postmortem brain (Table 1) . However, in other hands, there are no changes in basal respiratory capacity observed in R6/2 animals (Oliveira et al., 2007) . Moreover, in R6/2 animals, the effects of mhtt fragments on the respiratory capacity are mixed, with aconitase and complex IV defects reported in some cases (Aidt et al., 2013; Tabrizi et al., 2000) , while other analyses find no effects on these complexes (Yano et al., 2014) or late impairment (Goodman et al., 2008) .
Collectively, the average results of bioenergetic analysis in mouse models vary depending on whether they express the truncated mHtt gene or the FL form. The severe early onset fragments models are reminiscent of end-stage neurodegeneration observed in human HD brain, where complex II is lost, while a large number of FL mouse models do not seem to display bioenergetic defects, and are more similar to presymptomatic human HD brain. If these correlations are correct, the results align better with human disease in that mitochondrial dysfunction is observed late in disease progression, but not early on.
Calcium handling in rodent models for HD
It is expected that the calcium sensitivity would be commensurate with OCR and would be informative in interpreting the OCR results. OCR is tightly controlled by intramitochondrial Ca 2+ in a mechanism designed to ensure that ATP synthesis is closely coupled to the energetic needs of the cell. The consequent activation of oxidative metabolism increases the supply of reducing equivalents (NADH and FADH 2 ) to drive respiratory chain activity and ATP synthesis, while a decrease in calcium dynamics can lead to premature mitochondrial transition pore opening (MTP), cytochrome c release, and initiation of the cell death. The concentration of calcium required to induce membrane depolarization is thought to be a measure of mitochondrial integrity. However, in several mouse models of HD, the threshold calcium level that triggers mitochondrial transition pore opening (MTP) does not align with measures of OCR or with CAG tract length in an obvious way (Choo et al., 2004; Oliveira et al., 2007; Panov et al., 2002; Lim et al., 2008; Milakovic et al., 2006; Brustovetsky et al., 2005) . In one analysis, mhtt decreases the Ca +2 threshold in MT from lympholasts of HD patients and from YAC72 HD mouse models (Panov et al., 2002) . However, no reductions in calcium handling capability versus controls were observed in purified striatum MT isolated from R6/2 or from HD knock-in mice harboring a Q20, Q50, Q92 and Q111 in another analysis (Brustovetsky et al., 2005) . Rather, striatal MT were more resistant to calcium challenge relative to controls between 5 and 12 months in knock-in Q92 mice and between 8 and 12 weeks in HdhQ(111/111) mice (Brustovetsky et al., 2005) . It should be noted that here again the STHdh Q 111 cells (Lim et al., 2008; Milakovic et al., 2006 ) displayed a significant reduction in Ca 2+ uptake capacity compared with the HdhQ(111/111) mice from which they were derived (Brustovetsky et al., 2005) .
Since fragment and full-length models may provide distinct outcomes, a side by side comparison of OCR and calcium dynamics in YAC128 (8wks), R6/2 (12-13wks) and HthQ150/150 animals has been informative (Oliveira et al., 2007; Hamilton et al., 2015) . When assayed together under identical conditions, there were no changes in basal respiratory capacity observed in any of the three models in unstimulated neurons. Interestingly, however, the R6/2 and the YAC128 mice shared the property that they are better able to handle calcium as compared with respective wild-type littermates (Oliveira et al., 2007) , consistent with the results of Brustovetsky (Brustovetsky et al., 2005; Hamilton et al., 2015) . These differences are notable in that the R6/2 line harbors an N-terminal G Model MAD-10883; No. of Pages 17 A.A. Polyzos, C.T. McMurray / Mechanisms of Ageing and Development xxx (2016) (Oliveira et al., 2007) . The bioenergetic and calcium handling capacities are expected to rise together, but the differences in Ca 2+ threshold necessary to trigger MPT pore opening (increase or decrease) are often observed under condition of equal respiratory capacity, and do not appear to depend in obvious ways on whether the FL or the truncated fragment of mhtt is expressed. Collectively, the conflicting results as to OCR, calcium threshold, and membrane potential make it difficult to draw conclusions as to whether mitochondrial dysfunction is a causative feature of toxicity in isolated MT. There are gaps in our understanding. For example, whether a higher resistance to mPTP opening is beneficial is not formally known. MT are easily damaged during isolation. Thus, more attention should be paid to the use of intact neurons, which are more resistant to damage relative to MT. The disadvantage of this approach, however, is that viable neurons can only be isolated during embryonic stages, while neuronal death occurs much later, and it is not clear that the key events in toxicity will be obvious in embryonic cells. The recent development or synaptosomes may be a solution. Synaptosomes are "pinched off" nerve terminals, which provide a system to assess mitochondrial function in neurons within a physiological milieu. While they, admittedly, report on MT only at the synapses, synaptosomes can be isolated at any age, providing the possibility for more accurate measures of agerelated properties of brain MT, without the need to isolate them in purified form. Minimally, there is a clear need for normalized conditions, buffers, side-by-side comparison, and even instrumentation to resolve functional issues.
Oxidative damage in nuclear and mitochondria DNA
MT is the principal source of endogenous cellular ROS, and it follows that impairment of the ETC in the MT of mhtt expressing systems would manifest as an increase in the oxidative damage, which has long been proposed as a mechanism of aging and neurodegeneration. But is there evidence for increased oxidative damage as a cause for HD toxicity, and does this damage arise from dysfunctional MT? This question is not easy to address in human HD post-mortem brain since oxidative damage due to postmortem delay cannot be quantified. Moreover, MT fission-fusion dysfunction in HD cell culture models (Bossy-Wetzel et al., 2008; Shirendeb et al., 2012; Song et al., 2011) makes it difficult to quantify whether an accumulation of oxidative damage is a causative event for toxicity. Remarkably, despite the popular hypotheses, there is a paucity of data that links OCR defects, if they occur, with oxidative damage in the mitochondrial genome, damage in the nuclear genome, or to toxicity. While emerging evidence supports the idea that oxidative damage from MT contributes to toxicity (reviewed in Ayala-Pena, 2013; Johri and Beal, 2012) , in most cases, a rise in oxidative damage is assumed, but not measured.
This situation has changed recently. Oxidative lesion levels has been measured directly in DNA of mouse brains from HdhQ(150/150) mouse models (Budworth et al., 2015; Polyzos et al., 2016) and in STHdhQ 111 cells (Siddiqui et al., 2012) . Quantitative PCR (Polyzos et al., 2016 ) and 8-oxo-G antibodies (Polyzos et al., 2016) confirm a rise in oxidative DNA damage in both mtDNA and in nuclear DNA. But is this increase of oxidative DNA lesions relevant to disease? In the FL HdhQ(150/150) mouse model, there is no observable oxidative damage in MT at 12-16wks, but damage becomes obvious at 60-80wks, well after motor deficits are observed (Budworth and McMurray, 2016; Polyzos et al., 2016) . These data suggest that oxidation in the mitochondrial genome occurs, but is late in disease progression, and is not the primary cause of toxicity. Mass spectrometry and quantitative PCR also confirm an elevation in oxidative DNA damage in R6/1 animals in nuclear DNA is elevated with age (Kovtun et al., 2007) , and in muscle MT from R6/2 mice (Ayala-Pena, 2013), respectively. In cells, although there is no correlate with age, an increase in DNA lesions in MT from STHdhQ 111 cells relative to controls occurs concomitantly with a lower spare respiratory capacity (Siddiqui et al., 2012) . All of these results indicate that elevated oxidative damage in MT occurs, but, at least in animals, is not measureable in the mitochondrial genome until late in disease progression.
However, the elevated oxidative lesion in the nuclear DNA causes genetic instability at the huntingtin locus, and manifests as somatic expansion of the CAG repeat, an underlying cause of the disease. Addition of peroxide increases instability of repetitive DNA and increases the CAG mutation load in R6/1 animals ( Kovtun et al., 2007) , and expansion arises in the process of removing oxidized bases. Specifically, the relevant DNA glycosylases and endonucleases create a single strand gap when they remove oxidized bases, and the break facilitates the formation of the hairpin precursors for expansion (McMurray, 2010; Kovtun et al., 2007; Usdin et al., 2015) . Indeed, knock-out of key DNA repair enzymes, OGG1 (8-Oxoguanine DNA Glycosylase) (Kovtun et al., 2007) , XPA (Xeroderma Pigmentosum, Complementation Group A) (Hubert et al., 2011) , and NEILS1 (Nei Like DNA Glycosylase 1) (Mollersen et al., 2012) in HD R6/1 animals decreases expansion. Thus, the inability to make the break in DNA by these repair proteins prevents further expansion. The level of OGG1 also has an impact on the degree of somatic expansion (Goula et al., 2009) . Although other models are proposed (Freudenreich and Usdin, 2015; McMurray, 2010) , these features have confirmed the long suspected idea that, in some non-dividing cells, expansion is likely to occur in the process of removing oxidative damage in DNA through a base excision repair process. Going one step further, loss of somatic expansion in the Hdh(Q150/Q150)/ogg1(-/-) crosses delays the onset of disease by around 7-10 months relative to their Hdh(Q150/Q150)/ogg1(+/+) littermates, although they both inherit a similar disease-length HD allele (Budworth et al., 2015; Budworth and McMurray, 2016) . Collectively, these results provide evidence that oxidative damage directly causes DNA expansion and contributes to toxicity, as suppression of the somatic mutation delays its onset.
But does the oxidative damage arise directly from MT. Compelling evidence to support such a hypothesis comes from therapeutic anti-oxidants that target MT directly (Johri and Beal, 2012) . Dietary supplementation with naturally occurring Vitamin E and Coenzyme Q 10 (Johri and Beal, 2012; Oyewole et al., 2014) has been a significant focus of antioxidant therapeutics for HD treatment. CoQ 10 (ubiquinone), an essential biological cofactor of the electron transport chain, functions as an important antioxidant in MT and in lipid membranes. CoQ 10 treatment improves early motor deficits in several HD mouse models (Andrich et al., 2004; Smith et al., 2006; Schilling et al., 2004; Hickey et al., 2012) . Despite these positive preclinical outcomes, clinical trials for CoQ 10 for HD patients did not show efficacy when treatment started after symptoms began and unrealistically large amounts were administered (Chandra et al., 2014; Shannon and Fraint, 2015) . The sources of the anti-oxidant failure in HD clinical trials are unclear. It has been suggested that CoQ 10 may be beneficial in HD when treatment is begun at early stages of the disease, and that dosage will be critical. However, at least in part, the failure is likely due to cationic charge of CoQ10. Mitochondrial entry of cationic antioxidants such as MitoQ requires the charge gradient of MT (Oyewole et al., 2014 ), yet loss of the charge gradient is a major feature of dying neurons. If the gradients are not intact, CoQ 10 -related compounds cannot gain access to the inner mitochondrial membrane and the ETC and, in turn, cannot reduce oxidative damage.
Recently, a neutral electron scavenger, which enters MT independently of cationic charge, provides a direct link between with repsiration of MT, DNA oxidation, and expansion. XJB-5-131 is a synthetic radical scavenger that targets an antioxidant to the inner mitochondrial membrane (Polyzos et al., 2016 and refs within) . In the HdhQ(150/150) animals, XJB-5-131 targeting attenuates the decline in Rota-Rod performance, suppresses weight loss, and attenuates mitochondrial lesion load and mitochondrial copy number if treatment begins at a young age before phenotypes develop (Xun et al., 2012) , and attenuates or reverses the effects of disease if treatment begins after disease onset (Polyzos et al., 2016) . In aging animals with well-developed pathology, XJB-5-131 treatment promotes weight gain, attenuates neuronal loss, reduces inclusion formation, prevents the performance decline in multiple motor tests, suppresses somatic expansion, and decreases oxidative damage in the brains of aging HdhQ(150/150) animals relative to age-matched vehicle-treated HdhQ(150/150) or HdhQ(wt/wt) animals. Most important in addressing the relationship to oxidative damage, treatment with XJB-5-131 attenuates mitochondrial lesion load, mitochondrial copy number, and somatic expansion (Budworth et al., 2015) . The staining with 8-oxo-G antibodies is prominent in MT and colocalize with the Voltage-dependent anion channel (VDAC), which is a mitochondrial marker (Polyzos et al., 2016) , and is also reversed by XJB-5-131. In sum, treatment with this electron scavenger reduces oxidative damage in MT and suppresses both somatic expansion and disease phenotypes. These experiments provide strong evidence that elevated oxidative damage results in lesion load, but do not, address whether oxidative damage is equivalent to mitochondrial dysfunction. Indeed, as discussed above there is little respiratory change in MT in HdhQ(150/150) animals at 11-20wks, a time when motor impairment is obvious. These results could imply that damage arises from normal age-dependent mitochondrial respiration, or that metabolic dysfunction rather than mitochondrial dysfunction occurs in HD patients. The functional stress placed on MT, however, could cause their dysfunction later in disease progression. Simultaneous analysis of motor dysfunction, mitochondrial respiration capacity, and oxidative status with age in the same system will be needed to fully sort out the relationships.
Conclusions
We have progressed quite a bit in our understanding from the early discoveries that lay the basis for mitochondrial dysfunction as a factor in neuronal cell death. Defects are universally observed late in disease progression, indicating the MT are no longer functioning normally. However, analysis of late-stage disease is a prophecy fulfilled, rather than a firm test of the hypothesis that mitochondrial dysfunction causes toxicity. The defects at these stages may result from a myriad of other cellular processes gone awry. In fact, it is important to note that not all MT are affected in the HD brain even in grade 1 disease. The regional specificity implies that MT dysfunction develops in response to its changing environment.
The nature of the changing environment is unknown and speculative. Good candidates include a general reduction of mitochondrial gene expression transcription by PGC-1alpha (Weydt et al., 2006) , or mHtt interactions with Dyanmin-related protein 1 (DRP1) (Bossy-Wetzel et al., 2008; Shirendeb et al., 2012; Song et al., 2011) or the inner mitochondrial transporter protein 23 (TIM23) (Yano et al., 2014) , which alter the dynamics of MT at both the DNA and protein level. DRP1 regulates biogenesis, mitochondrial copy number, and integrity of MT, whereas TIM23 is responsible for importing proteins destined for the matrix or inner membrane. However, all come with strengths and weaknesses as candidates. There is no mtDNA copy number defect at early ages in mice, indicating that losing MT biogenesis is not the initial event in toxicity. Thirteen essential subunits of different ETC complexes are expressed in mitochondria, and do not need to be imported. However, loss of TIM23 would suppress import of proteins including many members of complexes that carry out intermediary metabolism and respiration. Whether protein import is functionally altered in humans is not known. However, in mice, a toxic N-terminal fragment inhibits protein import in in vitro assays of synaptosomes isolated from R6/2 mouse brain as early as 3 weeks of age, but import inhibition occurs in the absence of deficits in respiratory function in MT isolated from presymptomatic animals (Yano et al., 2014) . The disconnect between these two features is not consistent with MT as an initiating defect.
Many proteins interact with mHtt, however, none are exclusive to a particular brain region or are necessarily distinct from those of Htt, despite small changes in affinity as judged by western analysis (Harjes and Wanker, 2003) . Thus, they are less attractive as early defects. Identifying a single most important process in HD based on protein association has been difficult. PGC-1alpha expression is critical for expression of many mitochondrial genes. However, reduction in PGC-1alpha expression in HD brain is not restricted to the striatum. It has been speculated that cellular metabolism rather than mitochondrial defects per se is the underlying culprit. For example, low glucose uptake is a characteristic feature of HD and an early defect. Indeed, metabolic disturbances such as in altered fatty acid levels and glucose metabolism are widely reported. Compromise in the metabolism of MT is a good explanation for the sensitivity to pore opening, which may, in the end, exacerbate malfunctions induced by DRP1 or TIM23. However, fatty acid defects in plasma from human HD patients have been difficult to reproduce, and the basis for the glucose defect is unknown.
The cause or consequence of mitochondrial dysfunction is a classic story of the chicken and the egg, and perhaps we will always be speculating as to the most important initiating event that leads to toxicity. It has been suggested that toxicity is the accumulation of many faulty interactions that creates a threshold for toxicity. However, arguing the other side, if so many defects occur, it is surprising that patients can live normal lives for decades. Nonetheless, the search for the source is well worth the effort. The history of excellent work by a field of dedicated researchers has allowed us to build on the models that emerged from early discovery of brain defects in HD patients, and our deepening understanding will propel future discoveries that may lead to therapeutics.
